Investors Alert: Geron and Potential Securities Class Action
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson encourages investors who suffered losses exceeding $100,000 in Geron to contact him directly to discuss their options.
If you sustained losses that went beyond $100,000 in Geron during the relevant timeframe and are interested in knowing your legal rights, reach out to Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Faruqi & Faruqi, LLP, an esteemed national securities law firm, is presently investigating potential claims against Geron Corporation (NASDAQ: GERN). Investors are reminded of the looming deadline to take on the role of lead plaintiff in a federal securities class action filed against the Company. Acting quickly is essential.
About Faruqi & Faruqi, LLP
Faruqi & Faruqi operates with offices across major states including New York, Pennsylvania, California, and Georgia, and has been a leading national securities law firm since 1995. The firm has successfully recovered hundreds of millions of dollars for investors, establishing a robust reputation within securities litigation.
The Case Against Geron
The complaint alleges that Geron Corporation and its executives breached federal securities laws by disseminating false and misleading statements. These included overly optimistic assertions regarding Geron's ambitions to address a significant unmet need in the drug market while downplaying the challenges affecting Rytelo's sales.
On February 26, 2025, Geron disclosed disappointing financial results for the fourth quarter of fiscal 2024. The report indicated that sales for Rytelo had not met expectations and growth had stalled, attributing this stagnation to seasonal effects, increased competition, and issues related to the drug's monitoring requirements.
This announcement led to a sharp decline in Geron's stock price. Following the release of these results, shares priced at $2.37 dipped to $1.61 within just a day of trading, marking a staggering drop of roughly 32.07% in share value.
Understanding Your Role as Lead Plaintiff
In a securities class action, the lead plaintiff is typically the investor with the greatest financial stake in the anticipated relief and one who can represent the interests of other class members. Anyone from the potential class can apply to take on this role through legal counsel or opt to remain a member without active participation, which does not impact their eligibility for recovery.
Taking Action and Reporting Information
Faruqi & Faruqi, LLP encourages anyone with relevant information regarding Geron's business practices to come forward. This includes former employees, whistleblowers, shareholders, or those who have insights that could contribute to the ongoing case.
For detailed information about the Geron class action, please visit www.faruqilaw.com/GERN or call Faruqi & Faruqi partner Josh Wilson directly.
Frequently Asked Questions
What is the role of the lead plaintiff in a class action?
The lead plaintiff represents the interests of all class members and plays a crucial role in directing the litigation process.
What are the critical dates I should be aware of?
The announcement indicates a May 12, 2025, deadline for those interested in serving as lead plaintiffs.
How can I contact Faruqi & Faruqi for more information?
You can call them directly at 877-247-4292 or find more details on their website.
What are the potential implications of the class action?
Depending on the court's ruling, affected investors may receive compensation for losses sustained due to misleading statements.
Who can participate in the class action?
Any investors who suffered losses during the specified timeframe can participate in the class action, either by seeking lead plaintiff status or opting to remain as class members.
